Cantor Fitzgerald analyst Brandon Folkes maintained a Buy rating on Collegium Pharmaceutical (COLL) today and set a price target of $35. The company’s shares closed yesterday at $17.99.
Folkes said:
“We expect upwards earnings revisions to levels not reflected in FactSet consensus to drive COLL shares higher. Valuation Summary We use a blend of DCF and EV/EBITDA to arrive at our $35 price target. The Disclosure Section may be found on pages 5 – 6.Valuation We use a blend of DCF and EV/EBITDA to arrive at our $35 price target.”
According to TipRanks.com, Folkes is a 3-star analyst with an average return of 4.8% and a 45.9% success rate. Folkes covers the Healthcare sector, focusing on stocks such as Opiant Pharmaceuticals Inc, Eagle Pharmaceuticals Inc, and ANI Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Collegium Pharmaceutical with a $32.67 average price target, implying an 81.6% upside from current levels. In a report issued on March 4, H.C. Wainwright also maintained a Buy rating on the stock with a $30 price target.
See today’s analyst top recommended stocks >>
Based on Collegium Pharmaceutical’s latest earnings release for the quarter ending December 31, the company reported a quarterly net profit of $9.09 million. In comparison, last year the company had a GAAP net loss of $17.4 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Collegium Pharmaceutical, Inc. operates as a pharmaceutical company, which engages in the developing and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases.
